{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:47:51Z","timestamp":1787021271774,"version":"build-2736575974"},"reference-count":73,"publisher":"The Endocrine Society","issue":"10","license":[{"start":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T00:00:00Z","timestamp":1720483200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100005851","name":"Shahid Beheshti University of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005851","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Antithyroid drugs (ATD) are the treatment of choice for the majority of patients with Graves\u2019 hyperthyroidism worldwide. However, relapse of hyperthyroidism after withdrawal of arbitrarily chosen conventional 12 to 18 months of therapy is very common. In the last 2 decades, many studies have shown that treatment with long-term ATD (LT-ATD) is effective and safe in the maintenance of euthyroidism. In addition, it has been reported that serum TSH receptor antibody may not decrease permanently before 5 to 6 years of ATD treatment, and clinical trials have shown that \u22655 years of ATD treatment is accompanied by remission in the majority of patients with Graves\u2019 hyperthyroidism. The objective of this article is to discuss the optimal time to withdraw of conventional ATD therapy, to illustrate the decision-making of the management of recurrent hyperthyroidism, to review the proper management of LT-ATD, and to generate suggestions for lifelong ATD treatment by discussing 4 scenarios of decision-making in patients with Graves\u2019 disease.<\/jats:p>","DOI":"10.1210\/clinem\/dgae456","type":"journal-article","created":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T14:01:58Z","timestamp":1720533718000},"page":"e1881-e1888","source":"Crossref","is-referenced-by-count":22,"title":["Approach to the Patient Considering Long-term Antithyroid Drug Therapy for Graves\u2019 Disease"],"prefix":"10.1210","volume":"109","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6470-2517","authenticated-orcid":false,"given":"Fereidoun","family":"Azizi","sequence":"first","affiliation":[{"name":"Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences , Tehran 1985717413, I.R.Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8568-7419","authenticated-orcid":false,"given":"Ladan","family":"Mehran","sequence":"additional","affiliation":[{"name":"Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences , Tehran 1985717413, I.R.Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6850-0090","authenticated-orcid":false,"given":"Hengameh","family":"Abdi","sequence":"additional","affiliation":[{"name":"Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences , Tehran 1985717413, I.R.Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9433-9408","authenticated-orcid":false,"given":"Atieh","family":"Amouzegar","sequence":"additional","affiliation":[{"name":"Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences , Tehran 1985717413, I.R.Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2024,7,9]]},"reference":[{"issue":"10","key":"2024091609285025000_dgae456-B1","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1089\/thy.2016.0229","article-title":"2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis","volume":"26","author":"Ross","year":"2016","journal-title":"Thyroid"},{"issue":"2","key":"2024091609285025000_dgae456-B2","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1056\/NEJMc1614624","article-title":"Graves\u2019 disease","volume":"376","author":"Smith","year":"2017","journal-title":"N Engl J Med"},{"key":"2024091609285025000_dgae456-B3","first-page":"155","volume-title":"Radioiodine and Thyroid Disease: the Beginning","author":"Becker","year":"1996"},{"issue":"3","key":"2024091609285025000_dgae456-B4","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1089\/thy.1994.4.313","article-title":"Ted Astwood's intellectual legacy: some personal viewpoints","volume":"4","author":"Hershman","year":"1994","journal-title":"Thyroid"},{"issue":"2","key":"2024091609285025000_dgae456-B5","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1089\/thy.1991.1.129","article-title":"Differences and similarities in the diagnosis and treatment of Graves\u2019 disease in Europe, Japan, and the United States","volume":"1","author":"Wartofsky","year":"1991","journal-title":"Thyroid"},{"issue":"3","key":"2024091609285025000_dgae456-B6","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1089\/thy.2019.0132","article-title":"Patterns of use, efficacy, and safety of treatment options for patients with Graves\u2019 disease: a nationwide population-based study","volume":"30","author":"Brito","year":"2020","journal-title":"Thyroid"},{"issue":"6","key":"2024091609285025000_dgae456-B7","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1530\/EJE-20-1490","article-title":"Preferences of patients and clinicians for treatment of Graves\u2019 disease: a discrete choice experiment","volume":"184","author":"van Kinschot","year":"2021","journal-title":"Eur J Endocrinol"},{"issue":"Suppl","key":"2024091609285025000_dgae456-B8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5812\/ijem.102270","article-title":"A new perspective in the management of Graves\u2019 hyperthyroidism","volume":"18","author":"Azizi","year":"2020","journal-title":"Int J Endocrinol Metab"},{"issue":"2","key":"2024091609285025000_dgae456-B9","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1507\/endocrj.K10E-262","article-title":"Drug discontinuation after treatment with minimum maintenance dose of an antithyroid drug in Graves\u2019 disease: a retrospective study on effects of treatment duration with minimum maintenance dose on lasting remission","volume":"58","author":"Konishi","year":"2011","journal-title":"Endocr J"},{"issue":"10","key":"2024091609285025000_dgae456-B10","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1007\/BF03346433","article-title":"Long-term follow-up of patients with hyperthyroidism due to Graves\u2019 disease treated with methimazole. Comparison of usual treatment schedule with drug discontinuation vs continuous treatment with low methimazole doses: a retrospective study","volume":"31","author":"Mazza","year":"2008","journal-title":"J Endocrinol Invest"},{"issue":"5","key":"2024091609285025000_dgae456-B11","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1530\/eje.0.1470583","article-title":"Predictors of outcome and comparison of different drug regimens for the prevention of relapse in patients with Graves\u2019 disease","volume":"147","author":"Nedreb\u00f8","year":"2002","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"2024091609285025000_dgae456-B12","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1007\/s40618-021-01730-1","article-title":"Appropriate duration of antithyroid drug treatment as a predictor for relapse of Graves\u2019 disease: a systematic scoping review","volume":"45","author":"Azizi","year":"2022","journal-title":"J Endocrinol Invest"},{"issue":"4","key":"2024091609285025000_dgae456-B13","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1210\/jcem-30-4-540","article-title":"Prediction of the long-term results of antithyroid drug therapy for thyrotoxicosis","volume":"30","author":"Alexander","year":"1970","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2024091609285025000_dgae456-B14","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1507\/endocrj1954.25.377","article-title":"Long term antithyroid drug therapy for intractable cases of Graves\u2019 disease","volume":"25","author":"Shizume","year":"1978","journal-title":"Endocrinol Jpn"},{"issue":"22","key":"2024091609285025000_dgae456-B15","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1001\/jama.1979.03300220020015","article-title":"Long-term antithyroid treatment in hyperthyroidism","volume":"242","author":"Slingerland","year":"1979","journal-title":"JAMA"},{"issue":"4","key":"2024091609285025000_dgae456-B16","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1530\/eje.1.01993","article-title":"A systematic review of drug therapy for Graves\u2019 hyperthyroidism","volume":"153","author":"Abraham","year":"2005","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"2024091609285025000_dgae456-B17","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1530\/eje.1.01904","article-title":"Effect of long-term continuous methimazole treatment of hyperthyroidism: comparison with radioiodine","volume":"152","author":"Azizi","year":"2005","journal-title":"Eur J Endocrinol"},{"issue":"10","key":"2024091609285025000_dgae456-B18","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1089\/thy.2016.0652","article-title":"Long-term antithyroid drug treatment: a systematic review and meta-analysis","volume":"27","author":"Azizi","year":"2017","journal-title":"Thyroid"},{"issue":"11","key":"2024091609285025000_dgae456-B19","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1007\/s40618-019-01054-1","article-title":"Safety of long-term antithyroid drug treatment? A systematic review","volume":"42","author":"Azizi","year":"2019","journal-title":"J Endocrinol Invest"},{"issue":"3","key":"2024091609285025000_dgae456-B20","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1089\/thy.2010.0181","article-title":"Outcome of very long-term treatment with antithyroid drugs in Graves\u2019 hyperthyroidism associated with Graves\u2019 orbitopathy","volume":"21","author":"Elbers","year":"2011","journal-title":"Thyroid"},{"issue":"1","key":"2024091609285025000_dgae456-B21","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s12020-021-02725-x","article-title":"The longer the antithyroid drug is used, the lower the relapse rate in Graves\u2019 disease: a retrospective multicenter cohort study in Korea","volume":"74","author":"Park","year":"2021","journal-title":"Endocrine"},{"issue":"12","key":"2024091609285025000_dgae456-B22","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1089\/thy.2015.0195","article-title":"Outcomes in relapsed Graves\u2019 disease patients following radioiodine or prolonged low dose of methimazole treatment","volume":"25","author":"Villagelin","year":"2015","journal-title":"Thyroid"},{"issue":"9","key":"2024091609285025000_dgae456-B23","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1089\/thy.2019.0180","article-title":"Increased remission rates after long-term methimazole therapy in patients with Graves\u2019 disease: results of a randomized clinical trial","volume":"29","author":"Azizi","year":"2019","journal-title":"Thyroid"},{"issue":"4","key":"2024091609285025000_dgae456-B24","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.eprac.2023.01.006","article-title":"Long-term follow-up of graves orbitopathy after treatment with short-or long-term methimazole or radioactive iodine","volume":"29","author":"Azizi","year":"2023","journal-title":"Endocr Pract"},{"issue":"5","key":"2024091609285025000_dgae456-B25","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1530\/EJE-15-0306","article-title":"Hyperthyroidism is associated with work disability and loss of labour market income. A Danish register-based study in singletons and disease-discordant twin pairs","volume":"173","author":"Brandt","year":"2015","journal-title":"Eur J Endocrinol"},{"issue":"8","key":"2024091609285025000_dgae456-B26","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1089\/thy.2016.0044","article-title":"Quality-of-life impairments persist six months after treatment of Graves\u2019 hyperthyroidism and toxic nodular goiter: a prospective cohort study","volume":"26","author":"Cramon","year":"2016","journal-title":"Thyroid"},{"issue":"3","key":"2024091609285025000_dgae456-B27","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1089\/thy.2006.16.295","article-title":"Serum thyrotropin receptor antibodies concentrations in patients with Graves\u2019 disease before, at the end of methimazole treatment, and after drug withdrawal: evidence that the activity of thyrotropin receptor antibody and\/or thyroid response modify during the observation period","volume":"16","author":"Carella","year":"2006","journal-title":"Thyroid"},{"issue":"Suppl","key":"2024091609285025000_dgae456-B28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5812\/ijem.101139","article-title":"Long-term antithyroid drug treatment: trends in serum TSH and TSH receptor antibody changes in patients with Graves\u2019 disease","volume":"18","author":"Okamura","year":"2020","journal-title":"Int J Endocrinol Metab"},{"issue":"9","key":"2024091609285025000_dgae456-B29","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1089\/thy.2005.15.1047","article-title":"Sensitive thyrotropin and thyrotropin-receptor antibody determinations one month after discontinuation of antithyroid drug treatment as predictors of relapse in Graves\u2019 disease","volume":"15","author":"Quadbeck","year":"2005","journal-title":"Thyroid"},{"issue":"10","key":"2024091609285025000_dgae456-B30","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1055\/s-0035-1555759","article-title":"Outcome prediction of treatment of Graves\u2019 hyperthyroidism with antithyroid drugs","volume":"47","author":"Piantanida","year":"2015","journal-title":"Horm Metab Res"},{"issue":"4","key":"2024091609285025000_dgae456-B31","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1210\/jc.2015-3644","article-title":"Predicting the risk of recurrence before the start of antithyroid drug therapy in patients with Graves\u2019 hyperthyroidism","volume":"101","author":"Vos","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2024091609285025000_dgae456-B32","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1007\/s40618-018-0918-9","article-title":"Antithyroid drug treatment for Graves\u2019 disease: baseline predictive models of relapse after treatment for a patient-tailored management","volume":"41","author":"Masiello","year":"2018","journal-title":"J Endocrinol Invest"},{"issue":"4","key":"2024091609285025000_dgae456-B33","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1530\/EJE-16-0986","article-title":"External validation of the GREAT score to predict relapse risk in Graves\u2019 disease: results from a multicenter, retrospective study with 741 patients","volume":"176","author":"Struja","year":"2017","journal-title":"Eur J Endocrinol"},{"issue":"10","key":"2024091609285025000_dgae456-B34","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1055\/a-0974-3991","article-title":"External validation of the GREAT score in Turkish patients with graves\u2019 hyperthyroidism treated with the titration regimen method of antithyroid drugs: a multicenter study","volume":"51","author":"Zuhur","year":"2019","journal-title":"Horm Metab Res"},{"issue":"8","key":"2024091609285025000_dgae456-B35","first-page":"477","article-title":"Long-term continuous methimazole or radioiodine treatment for hyperthyroidism","volume":"15","author":"Azizi","year":"2012","journal-title":"Arch Iran Med"},{"issue":"10","key":"2024091609285025000_dgae456-B36","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1089\/thy.2019.0814","article-title":"Long-term treatment of hyperthyroidism with antithyroid drugs: 35 years of personal clinical experience","volume":"30","author":"Azizi","year":"2020","journal-title":"Thyroid"},{"issue":"Suppl","key":"2024091609285025000_dgae456-B37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5812\/ijem.101487","article-title":"Long-term treatment with antithyroid drugs: efficacy and safety","volume":"18","author":"Malboosbaf","year":"2020","journal-title":"Int J Endocrinol Metab"},{"issue":"5","key":"2024091609285025000_dgae456-B38","doi-asserted-by":"crossref","first-page":"e20183034","DOI":"10.1542\/peds.2018-3034","article-title":"Long-term methimazole therapy in juvenile Graves\u2019 disease: a randomized trial","volume":"143","author":"Azizi","year":"2019","journal-title":"Pediatrics"},{"issue":"3","key":"2024091609285025000_dgae456-B39","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1089\/thy.2016.0457","article-title":"2017 guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and the postpartum","volume":"27","author":"Alexander","year":"2017","journal-title":"Thyroid"},{"issue":"2","key":"2024091609285025000_dgae456-B40","doi-asserted-by":"crossref","first-page":"101631","DOI":"10.1016\/j.beem.2022.101631","article-title":"Long-term thionamide antithyroid treatment of Graves\u2019 disease","volume":"37","author":"Azizi","year":"2023","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"4","key":"2024091609285025000_dgae456-B41","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1159\/000490384","article-title":"2018 European Thyroid Association guideline for the management of Graves\u2019 hyperthyroidism","volume":"7","author":"Kahaly","year":"2018","journal-title":"Eur Thyroid J"},{"issue":"11","key":"2024091609285025000_dgae456-B42","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/j.eprac.2022.08.004","article-title":"Time to normalization and sustainable normal serum thyrotropin concentrations in patients with hyperthyroidism: comparison of methimazole and radioactive iodine treatments","volume":"28","author":"Azizi","year":"2022","journal-title":"Endocr Pract"},{"issue":"6","key":"2024091609285025000_dgae456-B43","doi-asserted-by":"crossref","first-page":"861","DOI":"10.3803\/EnM.2022.1476","article-title":"Efficacy and safety of long-term methimazole versus radioactive iodine in the treatment of toxic multinodular goiter","volume":"37","author":"Azizi","year":"2022","journal-title":"Endocrinol Metab"},{"issue":"9","key":"2024091609285025000_dgae456-B44","doi-asserted-by":"crossref","first-page":"4439","DOI":"10.1210\/jc.2004-0247","article-title":"Propylthiouracil before 131I therapy of hyperthyroid diseases: effect on cure rate evaluated by a randomized clinical trial","volume":"89","author":"Bonnema","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2024091609285025000_dgae456-B45","doi-asserted-by":"crossref","first-page":"4964","DOI":"10.1210\/jc.2016-2660","article-title":"Is a normal TSH synonymous with \u201ceuthyroidism\u201d in levothyroxine monotherapy?","volume":"101","author":"Peterson","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2024091609285025000_dgae456-B46","doi-asserted-by":"crossref","first-page":"e95385","DOI":"10.5812\/ijem.95385","article-title":"Systemic thyroid hormone status in treated Graves\u2019 disease","volume":"17","author":"Azizi","year":"2019","journal-title":"Int J Endocrinol Metab"},{"issue":"12","key":"2024091609285025000_dgae456-B47","first-page":"4533","article-title":"Systemic thyroid hormone status during levothyroxine therapy in hypothyroidism: a systematic review and meta-analysis","volume":"103","author":"McAninch","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2024091609285025000_dgae456-B48","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1089\/thy.2015.0345","article-title":"Effects of levothyroxine replacement or suppressive therapy on energy expenditure and body composition","volume":"26","author":"Samuels","year":"2016","journal-title":"Thyroid"},{"issue":"5","key":"2024091609285025000_dgae456-B49","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1046\/j.1365-2265.2002.01654.x","article-title":"Psychological well-being in patients on \u2018adequate\u2019doses of l-thyroxine: results of a large, controlled community-based questionnaire study","volume":"57","author":"Saravanan","year":"2002","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"2024091609285025000_dgae456-B50","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1089\/thy.2018.0315","article-title":"Impaired quality of life after radioiodine therapy compared to antithyroid drugs or surgical treatment for Graves\u2019 hyperthyroidism: a long-term follow-up with the thyroid-related patient-reported outcome questionnaire and 36-item short form health status survey","volume":"29","author":"T\u00f6rring","year":"2019","journal-title":"Thyroid"},{"key":"2024091609285025000_dgae456-B51","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jss.2017.06.091","article-title":"The long-term outcomes of thyroid function after subtotal thyroidectomy for Graves\u2019 hyperthyroidism","volume":"220","author":"Lin","year":"2017","journal-title":"J Surg Res"},{"issue":"6","key":"2024091609285025000_dgae456-B52","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1089\/ct.2019;31.230-233","article-title":"Long-term antithyroid drug treatment of patients with graves\u2019 disease","volume":"31","author":"Cooper","year":"2019","journal-title":"Clin Thyroidol"},{"issue":"1","key":"2024091609285025000_dgae456-B53","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1530\/EJE-07-0450","article-title":"TSH-receptor autoimmunity in Graves\u2019 disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study","volume":"158","author":"Laurberg","year":"2008","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2024091609285025000_dgae456-B54","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s13256-021-02788-4","article-title":"Efficacy of low-dose methimazole in control of multiple relapses of Graves\u2019 hyperthyroidism: a case report","volume":"15","author":"Azizi","year":"2021","journal-title":"J Med Case Rep"},{"issue":"Suppl","key":"2024091609285025000_dgae456-B55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5812\/ijem.101473","article-title":"Remission rate of Graves\u2019 disease and the trend of changes in serum TSH receptor antibodies in prolonged antithyroid drug treatment","volume":"18","author":"Villagelin","year":"2020","journal-title":"Int J Endocrinol Metab"},{"issue":"2","key":"2024091609285025000_dgae456-B56","doi-asserted-by":"crossref","first-page":"e220226","DOI":"10.1530\/ETJ-22-0226","article-title":"Long-term follow-up result of antithyroid drug treatment of Graves\u2019 hyperthyroidism in a large cohort","volume":"12","author":"Jin","year":"2023","journal-title":"Eur Thyroid J"},{"issue":"2)","key":"2024091609285025000_dgae456-B57","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s12020-023-03656-5","article-title":"Risk of recurrence at the time of withdrawal of short- or long-term methimazole therapy in patients with Graves\u2019 hyperthyroidism: a randomized trial and a risk-scoring model","volume":"84","author":"Azizi","year":"2024","journal-title":"Endocrine"},{"issue":"1","key":"2024091609285025000_dgae456-B58","first-page":"CD003420","article-title":"Antithyroid drug regimen for treating Graves\u2019 hyperthyroidism","volume":"2010","author":"Abraham","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"2024091609285025000_dgae456-B59","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12902-020-00670-w","article-title":"Control of Graves\u2019 hyperthyroidism with very long-term methimazole treatment: a clinical trial","volume":"21","author":"Azizi","year":"2021","journal-title":"BMC Endocr Disord"},{"issue":"4","key":"2024091609285025000_dgae456-B60","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/S2213-8587(19)30059-2","article-title":"Primary therapy of Graves\u2019 disease and cardiovascular morbidity and mortality: a linked-record cohort study","volume":"7","author":"Okosieme","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"2024091609285025000_dgae456-B61","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1097\/MED.0000000000000656","article-title":"Long-term antithyroid drug therapy","volume":"28","author":"Cooper","year":"2021","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"4","key":"2024091609285025000_dgae456-B62","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1089\/thy.2012.0500","article-title":"Graves\u2019 disease and toxic nodular goiter are both associated with increased mortality but differ with respect to the cause of death: a Danish population-based register study","volume":"23","author":"Brandt","year":"2013","journal-title":"Thyroid"},{"issue":"8","key":"2024091609285025000_dgae456-B63","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nrendo.2010.105","article-title":"Cardiovascular involvement in patients with different causes of hyperthyroidism","volume":"6","author":"Biondi","year":"2010","journal-title":"Nat Rev Endocrinol"},{"issue":"3","key":"2024091609285025000_dgae456-B64","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1089\/thy.2018.0320","article-title":"Duration of hyperthyroidism and lack of sufficient treatment are associated with increased cardiovascular risk","volume":"29","author":"Lillevang-Johansen","year":"2019","journal-title":"Thyroid"},{"issue":"9","key":"2024091609285025000_dgae456-B65","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJMra042972","article-title":"Antithyroid drugs","volume":"352","author":"Cooper","year":"2005","journal-title":"N Engl J Med"},{"issue":"1","key":"2024091609285025000_dgae456-B66","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1056\/NEJM198701013160104","article-title":"Induction of circulating activated suppressor-like T cells by methimazole therapy for Graves\u2019 disease","volume":"316","author":"T\u00f6tterman","year":"1987","journal-title":"N Engl J Med"},{"issue":"2","key":"2024091609285025000_dgae456-B67","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1365-2265.1986.tb01674.x","article-title":"Effect of the anti-thyroid drug methimazole on interleukin-1 and interleukin-2 levels in vitro","volume":"25","author":"Weetman","year":"1986","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"5","key":"2024091609285025000_dgae456-B68","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1124\/mol.60.5.972","article-title":"Methimazole as an antioxidant and immunomodulator in thyroid cells: mechanisms involving interferon-\u03b3 signaling and H2O2 scavenging","volume":"60","author":"Kim","year":"2001","journal-title":"Mol Pharmacol"},{"issue":"1","key":"2024091609285025000_dgae456-B69","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1186\/s40001-023-01210-7","article-title":"New-onset and relapsed Graves\u2019 disease following COVID-19 vaccination: a comprehensive review of reported cases","volume":"28","author":"Chen","year":"2023","journal-title":"Eur J Med Res"},{"issue":"8","key":"2024091609285025000_dgae456-B70","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.eprac.2023.05.005","article-title":"The incidence of Graves\u2019 hyperthyroidism before and after COVID-19 messenger RNA vaccination","volume":"29","author":"Endo","year":"2023","journal-title":"Endocr Pract"},{"issue":"2","key":"2024091609285025000_dgae456-B71","doi-asserted-by":"crossref","first-page":"e508","DOI":"10.1210\/clinem\/dgad582","article-title":"Graves\u2019 disease following COVID-19 vaccination: a population-based, matched case-control study","volume":"109","author":"Gorshtein","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2024091609285025000_dgae456-B72","doi-asserted-by":"crossref","first-page":"4776","DOI":"10.1210\/jc.2013-2569","article-title":"Analysis of 754 cases of antithyroid drug-induced agranulocytosis over 30 years in Japan","volume":"98","author":"Nakamura","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2024091609285025000_dgae456-B73","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1089\/thy.2011.0039","article-title":"Sustained control of Graves\u2019 hyperthyroidism during long-term low-dose antithyroid drug therapy of patients with severe Graves\u2019 orbitopathy","volume":"21","author":"Laurberg","year":"2011","journal-title":"Thyroid"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgae456\/58576555\/dgae456.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/109\/10\/e1881\/59136104\/dgae456.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/109\/10\/e1881\/59136104\/dgae456.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T05:31:54Z","timestamp":1726464714000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/109\/10\/e1881\/7709985"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,9]]},"references-count":73,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,7,9]]},"published-print":{"date-parts":[[2024,9,16]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgae456","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,10]]},"published":{"date-parts":[[2024,7,9]]}}}